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BACKGROUND
A vaccine to interrupt the transmission of tuberculosis is needed.
METHODS
We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of 
the M72/AS01E tuberculosis vaccine in Kenya, South Africa, and Zambia. Human 
immunodeficiency virus (HIV)–negative adults 18 to 50 years of age with latent 
M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in 
a 1:1 ratio) to receive two doses of either M72/AS01E or placebo intramuscularly 
1 month apart. Most participants had previously received the bacille Calmette–
Guérin vaccine. We assessed the safety of M72/AS01E and its efficacy against 
progression to bacteriologically confirmed active pulmonary tuberculosis disease. 
Clinical suspicion of tuberculosis was confirmed with sputum by means of a 
polymerase-chain-reaction test, mycobacterial culture, or both.
RESULTS
We report the primary analysis (conducted after a mean of 2.3 years of follow-up) 
of the ongoing trial. A total of 1786 participants received M72/AS01E and 1787 
received placebo, and 1623 and 1660 participants in the respective groups were 
included in the according-to-protocol efficacy cohort. A total of 10 participants in 
the M72/AS01E group met the primary case definition (bacteriologically confirmed 
active pulmonary tuberculosis, with confirmation before treatment), as compared 
with 22 participants in the placebo group (incidence, 0.3 cases vs. 0.6 cases per 
100 person-years). The vaccine efficacy was 54.0% (90% confidence interval [CI], 
13.9 to 75.4; 95% CI, 2.9 to 78.2; P = 0.04). Results for the total vaccinated efficacy 
cohort were similar (vaccine efficacy, 57.0%; 90% CI, 19.9 to 76.9; 95% CI, 9.7 to 
79.5; P = 0.03). There were more unsolicited reports of adverse events in the M72/
AS01E group (67.4%) than in the placebo group (45.4%) within 30 days after injec-
tion, with the difference attributed mainly to injection-site reactions and influenza-
like symptoms. Serious adverse events, potential immune-mediated diseases, and 
deaths occurred with similar frequencies in the two groups.
CONCLUSIONS
M72/AS01E provided 54.0% protection for M. tuberculosis–infected adults against ac-
tive pulmonary tuberculosis disease, without evident safety concerns. (Funded by 
GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598.)
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One quarter of the global popula-tion is estimated to be infected with My-cobacterium tuberculosis, and tuberculosis is 
the leading infectious cause of death worldwide.1,2 
There were an estimated 10.4 million new cases 
of tuberculosis and 1.7 million deaths from the 
disease in 2016. An effective tuberculosis vaccine 
for M. tuberculosis–infected persons could have a 
marked effect on tuberculosis control, including 
drug-resistant tuberculosis, through interruption 
of transmission.3,4 Modeling suggests that the 
most effective contribution to tuberculosis con-
trol would be a vaccine preventing pulmonary tu-
berculosis in adolescents and young adults.4 The 
only licensed tuberculosis vaccine, BCG (bacille 
Calmette–Guérin), does not offer substantial pro-
tection against pulmonary tuberculosis in M. tuber-
culosis–infected adults.5
The M72/AS01E (GlaxoSmithKline) candidate 
vaccine contains the M72 recombinant fusion pro-
tein derived from two immunogenic M. tuberculosis 
antigens (Mtb32A and Mtb39A), combined with the 
AS01 adjuvant system, which is also a component 
of the malaria vaccine (RTS,S/AS01, GlaxoSmith-
Kline) and recombinant zoster vaccine (Shingrix, 
GlaxoSmithKline). The Mtb39A and Mtb32A com-
ponents of the recombinant antigen elicited spe-
cific lymphoproliferation, interferon-γ production, 
or both in persons with latent and active tuber-
culosis.6-8 In phase 2 studies, M72/AS01E showed 
a clinically acceptable safety profile and induced 
humoral and cell-mediated immune responses in 
healthy and human immunodeficiency virus (HIV)–
infected persons, M. tuberculosis–infected adults and 
adolescents, and BCG-vaccinated infants (Table S1 
in the Supplementary Appendix, available with full 
text of this article at NEJM.org).9-16
Overall, nonclinical evaluations (antigen-selec-
tion approach and in vivo preclinical data) and 
clinical safety and immunogenicity evidence, based 
on the ability of the candidate vaccine to induce 
type 1 helper T cell–type responses, supported a 
proof-of-concept human trial, despite caveats as-
sociated with the available studies in animals.6-9,17-22 
We conducted a proof-of-concept phase 2b trial 
to evaluate M72/AS01E in preventing bacteriologi-
cally confirmed pulmonary tuberculosis in HIV-
negative adults with M. tuberculosis infection, de-
fined by a positive interferon-γ release assay. This 
population was selected on the basis of a higher 
incidence of pulmonary tuberculosis among per-
sons with a positive interferon-γ release assay than 
among those with a negative assay, which allowed 
a smaller sample for proof of concept.23
Me thods
Trial Design and Oversight
The trial is a multicenter, double-blind, random-
ized, placebo-controlled trial conducted in three 
African countries in which tuberculosis is endemic 
(Kenya, South Africa, and Zambia). The random-
ization was not stratified but was performed with 
the use of a minimization algorithm that ac-
counted for sex and center (for details, see the 
Supplementary Appendix). Eleven trial sites were 
selected on the basis of the local prevalence of 
tuberculosis and an ability to perform the trial 
according to Good Clinical Practice guidelines. 
The QuantiFERON-TB Gold In-Tube assay (QFT, 
Qiagen) was used at the manufacturer’s recom-
mended cutoff point to identify latent M. tuberculosis 
infection. The trial population is being followed 
up for 3 years after administration of M72/AS01E 
or placebo. A prespecified primary analysis was 
performed when all the participants had complet-
ed at least 2 years of follow-up. Immunogenicity 
and reactogenicity were assessed in a subgroup of 
300 participants. The final analysis after 3 years 
of follow-up and secondary trial objectives, includ-
ing cell-mediated immune responses, are not re-
ported here because these data are not yet mature.
The trial was undertaken in accordance with 
Good Clinical Practice guidelines and the Declara-
tion of Helsinki. The protocol (available at NEJM 
.org) was approved by ethics committees and 
regulatory authorities in each participating coun-
try. The trial was funded by GlaxoSmithKline 
Biologicals (trial sponsor) and Aeras. Authors who 
are employees of GlaxoSmithKline and Aeras were 
involved in the conception and design of the trial 
and the collection, analysis, and interpretation of 
data, and some of them were part of the core writ-
ing team (see the Supplementary Appendix for a 
list of authors’ contributions). All the authors 
vouch for the completeness and accuracy of the 
data and analyses presented and for the adherence 
of the trial to the protocol. All the authors re-
viewed and approved the manuscript before it was 
submitted for publication. All the participants 
provided written or witnessed oral informed 
consent.
Unblinded safety data were reviewed by an in-
dependent data monitoring committee. Only the 
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external statisticians and the members of the in-
dependent data monitoring committee are aware 
of the trial-group assignments at the level of indi-
vidual participant data. Anonymized individual 
participant data and study documents can be re-
quested for further research (see the data sharing 
statement, available at NEJM.org).
Population
Adults 18 to 50 years of age were eligible if they 
were healthy or had stable chronic medical con-
ditions, were HIV-negative, had no symptoms 
of tuberculosis, were QFT-positive, and had a 
sputum sample negative for M. tuberculosis at 
baseline on a polymerase-chain-reaction (PCR) 
assay (GeneXpert MTB/RIF, Cepheid). Information 
on the eligibility criteria and screening procedures 
is provided in the Supplementary Appendix.
Vaccination
Participants were randomly assigned to M72/AS01E 
or placebo in a 1:1 ratio. Two doses of M72/AS01E 
or placebo were administered intramuscularly 
(0.5 ml) into the deltoid 1 month apart. Informa-
tion on vaccine and placebo composition is pro-
vided in the Supplementary Appendix.
Efficacy End Points
The primary objective of the trial was to evaluate 
the efficacy of M72/AS01E to prevent active pul-
monary tuberculosis according to the first case 
definition (primary end point; see Table 1 for case 
definitions). Secondary trial objectives were vac-
cine efficacy according to additional case defini-
tions, as well as the immunogenicity, safety, and 
reactogenicity of the vaccine.
Evaluation of Safety and Reactogenicity
Serious adverse events, potential immune-medi-
ated diseases, and pregnancies were recorded until 
6 months after the second dose. Serious adverse 
events that were considered by the site investiga-
tors to be related to the trial regimen were re-
corded until the end of the trial. Unsolicited re-
ports of adverse events were recorded for 30 days 
after each dose. Local and systemic symptoms 
Case Definition
Clinical 
Suspicion†
Culture and PCR 
Results HIV Status Other Condition
First definition (primary end point): definite pulmo-
nary TB disease not associated with HIV infection
Yes Either test or both tests 
positive‡
Negative Sputum collected before initia-
tion of TB treatment
Definition used for the sensitivity analysis of the pri-
mary end point: definite pulmonary TB disease 
(any two positive sputum tests) not associated 
with HIV infection
Yes Any two tests positive§ Negative Sputum collected before initia-
tion of TB treatment
Second definition: definite PCR-positive pulmonary 
TB disease not associated with HIV infection
Yes Positive PCR assay  
and any result  
on culture‡
Negative Sputum collected before initia-
tion of TB treatment
Third definition: definite pulmonary TB, not associated 
with HIV infection
Yes Either test or both tests 
positive‡
Negative Sputum collected up to 4 wk after 
initiation of TB treatment
Fourth definition: definite pulmonary TB Yes Either test or both tests 
positive‡
Any Sputum collected up to 4 wk after 
initiation of TB treatment
Fifth definition: clinical TB (any location) —¶ —¶ Any Clinician has diagnosed TB 
 disease and has decided  
to treat patient
Modified fifth definition: clinical TB (any location) 
not associated with HIV infection
—¶ —¶ Negative Clinician has diagnosed TB 
 disease and has decided  
to treat patient
*  Possible deaths due to TB have not been included in any of the case definitions unless the case-definition criteria as stated were met. HIV 
denotes human immunodeficiency virus, and PCR polymerase chain reaction.
†  The participant presented with one or more of the following: cough for more than 1 or 2 weeks, fever for more than 1 week, night sweats, 
weight loss, pleuritic chest pain, hemoptysis, fatigue, or shortness of breath on exertion.
‡  Results are for any of the three sputum samples collected because of clinical suspicion.
§  Any two tests positive indicates at least two positive cultures, two positive PCR assays, or one positive culture and one positive PCR assay 
among all test results obtained from the three sputum samples collected because of clinical suspicion.
¶  This is not a mandatory part of the case definition.
Table 1. Case Definitions of Tuberculosis (TB).*
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were solicited from the immunogenicity subgroup 
with the use of diary cards for 7 days after each 
dose. Laboratory testing for clinical chemical and 
hematologic analyses was performed in the sub-
group on days 0, 7, 30, and 37. (For more on safety 
monitoring, see the Supplementary Appendix.)
Evaluation of Immunogenicity
Blood samples were collected from the immuno-
genicity subgroup before dose 1, at 1 month after 
dose 2, and annually until year 3. Anti-M72 IgG 
antibodies were measured with the use of enzyme-
linked immunosorbent assay (ELISA), as described 
previously (cutoff, 2.8 ELISA units per milliliter).13
Tuberculosis Surveillance
Surveillance of tuberculosis involved both active 
methods (visits, telephone calls, and text messag-
es) and passive methods (patient reports). Partici-
pants with clinical suspicion of pulmonary tuber-
culosis provided three sputum samples, which 
were collected over a period of 1 week, for PCR 
assay and liquid culture by Mycobacterial Growth 
Indicator Tube. Samples were preferably to be 
taken before initiation of tuberculosis treatment, 
but samples that were collected up to 4 weeks after 
treatment initiation were accepted (case definitions 
3 and 4 in Table 1). Diagnostic and treatment deci-
sions were made by treating physicians not in-
volved in the trial. HIV retesting and screening 
for diabetes (glycated hemoglobin) were performed 
in all participants with confirmed tuberculosis 
disease. (For more on surveillance activities, see 
the Supplementary Appendix.)
Statistical Analysis
Using a log-rank test with 80% power and assum-
ing a true vaccine efficacy of 70% (hazard ratio, 
30%) and a two-sided 10% significance level, we 
estimated that 21 cases of pulmonary tuberculo-
sis were required for a fixed-sample design with 
the assumption of proportional hazards. To ob-
tain 21 cases, assuming a mean yearly attack rate 
of 0.55% in the control group, 2 years of follow-
up for each participant, and an attrition rate of 
15% over the 2-year period, we calculated that 3506 
participants would need to be enrolled. As speci-
fied in the protocol, the primary analysis could 
occur after 21 cases had been identified or 24 
months of follow-up had been completed.
Vaccine efficacy was analyzed in the according-
to-protocol efficacy cohort, with the use of Cox 
proportional-hazards regression models (vaccine 
efficacy = 1 − hazard ratio) with 90% confidence 
intervals and P values for Wald tests. Descriptive 
post hoc 95% confidence intervals are also pro-
vided. The primary end point was met if the lower 
limit of the two-sided 90% confidence interval 
for vaccine efficacy against bacteriologically con-
firmed pulmonary tuberculosis (first case defi-
nition) was more than 0%. If the primary end 
point was met, the first secondary end point 
(vaccine efficacy for the second case definition) 
was to be analyzed according to the same suc-
cess criterion. A preplanned exploratory analysis 
compared the effect of six prespecified covariates 
(giving 14 subgroups) on vaccine efficacy (inter-
pretation should be performed cautiously, because 
the risk of having at least one false significant re-
sult ranges from 51 to 77%).
The total vaccinated cohort (all participants 
who received at least one dose of M72/AS01E or 
placebo) was used to assess safety. Analysis of 
immunogenicity was performed on the according-
to-protocol immunogenicity cohort for the sub-
group. Statistical analyses were performed with 
SAS software, version 9.2 or higher, on the SAS 
Drug Development system.
R esult s
Trial Population
Of 3575 participants who underwent randomiza-
tion, 3573 received at least one dose of M72/AS01E 
or placebo from August 2014 through November 
2015, and 3330 received both doses. The mean 
(±SD) age of the participants was 28.9±8.3 years; 
43% were women. The trial groups were balanced 
in terms of prespecified demographic characteris-
tics (Table S2 in the Supplementary Appendix).
Vaccine Efficacy
There were 3283 participants included in the 
according-to-protocol efficacy analysis (Fig. 1). 
A total of 10 cases of active pulmonary tubercu-
losis in the vaccine group and 22 cases in the pla-
cebo group met the primary case definition after 
a mean follow-up of 2.3±0.4 years (Table 2). The 
incidence of pulmonary tuberculosis (first case 
definition) per 100 person-years was 0.3 in the 
M72/AS01E group and 0.6 in the placebo group, 
with an overall vaccine efficacy of 54.0% (90% 
confidence interval [CI], 13.9 to 75.4; 95% CI, 
2.9 to 78.2; P = 0.04). An analysis that used a Cox 
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regression model with adjustment for country, 
sex, diabetes (yes or no), age (≤25 or >25 years), 
current smoking status (yes or no), and previous 
BCG vaccination (yes, no, or unknown) gave nearly 
identical results. Vaccine efficacy for the second 
case definition (secondary end point) was 58.3% 
(90% CI, 12.8 to 80.1; 95% CI, −0.5 to 82.7; 
P = 0.05), and vaccine efficacy ranged from 27.7% 
to 36.4% for protocol-defined case definitions 3 to 
5 (Table 2). Kaplan–Meier curves are shown in 
Figure 2 for the first case definition. Results were 
similar in the analysis of the total vaccinated 
efficacy cohort. The incidence of pulmonary tu-
berculosis (first case definition) per 100 person-
years in the total vaccinated cohort was 0.2 in the 
M72/AS01E group and 0.5 in the placebo group, 
with overall vaccine efficacy of 57.0% (90% CI, 
19.9 to 76.9; 95% CI, 9.7 to 79.5) (Table 2).
A planned sensitivity analysis of the first case 
definition was restricted to participants positive 
for M. tuberculosis on at least two diagnostic tests 
(culture, PCR assay, or both) performed on the 
sputa collected (Table S3 in the Supplementary 
Appendix). This analysis included 5 cases in the 
M72/AS01E group and 17 cases in the placebo 
group; the vaccine efficacy was 70.3% (90% CI, 
31.3 to 87.1; 95% CI, 19.4 to 89.0) (Table 2). Piece-
wise analysis of cases (first case definition) oc-
curring before versus after the median follow-up 
time (1.12 years) showed a vaccine efficacy of 
39.0% (90% CI, −42.5 to 73.9; 95% CI, −67.7 to 
77.8) in the first period and 66.5% (90% CI, 13.3 
to 87.0; 95% CI, −4.0 to 89.2) in the second period.
Prespecified subgroup analyses that used case 
definition 1 showed vaccine efficacy among men 
of 75.2% (P = 0.03) and among women of 27.4% 
(P = 0.52), and vaccine efficacy among participants 
25 years or age or younger of 84.4% (P = 0.01) 
and among those older than 25 years of age of 
10.2% (P = 0.82) (Table 3). A post hoc hierarchi-
cal test was performed to assess the interaction 
between trial group and sex (P = 0.31) and be-
tween trial group and age (P = 0.07) in the com-
plete model containing all main effects as well 
as the two interaction terms (Table S4 in the Sup-
plementary Appendix).
Reactogenicity and Safety
The percentage of participants who had at least 
one serious adverse event within 6 months after 
the last dose of either M72/AS01E or placebo was 
similar in the two groups (1.6% in the M72/AS01E 
group and 1.8% in the placebo group) (Table 4). 
One serious adverse event in each group was con-
sidered to be related to the trial regimen by trial 
investigators (pyrexia and hypertensive encepha-
lopathy, with blinding to trial-group assignment 
still in effect). Potential immune-mediated dis-
eases were reported by 2 participants in the 
M72/AS01E group and 5 in the placebo group. 
There were 24 deaths (14 trauma-related) dur-
ing the trial, with 7 in the M72/AS01E group 
(6 trauma-related) and 17 in the placebo group 
(8 trauma-related) (Table 4). No death was con-
sidered to be related to the trial regimen. One 
participant died of pneumonia, for whom there 
was also a suspicion of intestinal tuberculosis, 
but this latter diagnosis was not confirmed. Nei-
ther M72/AS01E nor placebo substantially af-
fected hematologic or biochemical findings (Fig. 
S1 in the Supplementary Appendix). A post hoc 
analysis showed 33 pregnancies among 1529 
women who received M72/AS01E or placebo, of 
which 28 resulted in delivery of a healthy infant. 
There were 3 ectopic pregnancies as well as one 
spontaneous abortion, and 1 pregnant woman 
was lost to follow-up. No birth defects were 
noted. Regular review by the independent data 
monitoring committee of unblinded safety data 
resulted in recommendations to continue the 
trial unchanged.
There were more unsolicited reports of adverse 
events in the M72/AS01E group (67.4%) than in 
the placebo group (45.4%). The excess was driv-
en by injection-site reactions and influenza-like 
symptoms (Table S5 in the Supplementary Appen-
dix). Swelling reactions larger than 100 mm in 
diameter were reported by 53 participants (3.0%) 
in the M72/AS01E group and by 1 participant in 
the placebo group. The median duration of these 
large swelling reactions was 4 days.
In the immunogenicity subgroup, local and 
systemic solicited symptoms were reported more 
frequently by M72/AS01E recipients than by pla-
cebo recipients (Table S6 in the Supplementary 
Appendix). Among local solicited symptoms, pain 
was the most frequently reported (81.8% of M72/
AS01E recipients and 34.4% of placebo recipients, 
with 24.3% and 3.3%, respectively, reporting grade 
3 pain). Redness and swelling were uncommon in 
both groups. Fatigue, headache, malaise, or my-
algia was reported by 58.1 to 68.9% of M72/AS01E 
recipients and 26.5 to 47.0% of placebo recipients. 
Fever higher than 38.0°C was reported by 18.9% 
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and 6.6%, respectively. Fever higher than 39.5°C 
was reported by 4.1% and 1.3%, respectively.
The immunogenicity results indicate that 100% 
of the participants in the M72/AS01E group had 
seroconversion at month 2 and 99% were sero-
positive at month 12 (Fig. S2 in the Supplementary 
Appendix).
Discussion
There is no tuberculosis vaccine recommended 
for use in M. tuberculosis–infected adults, who rep-
resent a reservoir of potential cases of active tuber-
culosis. Here, we found that protection against 
tuberculosis disease may be achieved by vaccina-
3575 Underwent randomization
8336 Participants were screened
4761 Were excluded
66 (1.4%) Withdrew consent (not owing
 to adverse event)
4276 (89.8%) Did not meet inclusion criteria 
or met exclusion criteria
149 (3.1%) Were lost to follow-up or moved 
from trial area
270 (5.7%) Had other reason
1786 Received at least 1 dose
of M72/AS01E and were included
in the total vaccinated cohort
1787 Received at least 1 dose
of placebo and were included
in the total vaccinated cohort
1 Was excluded from the
total efficacy cohort
4 Were excluded from the
total efficacy cohort
1787 Were assigned to receive M72/AS01E 1788 Were assigned to receive placebo
1785 Were included in the
total efficacy cohort
1783 Were included in the
total efficacy cohort
162 Were excluded from
the ATP efficacy cohort
123 Were excluded from
the ATP efficacy cohort
1 Did not receive M72/AS01E 1 Did not receive placebo
1623 Were included in the
ATP efficacy cohort
1660 Were included in the
ATP efficacy cohort
149 Were included in the immunogenicity
subgroup
151 Were included in the immunogenicity
subgroup
28 Were excluded from the
ATP immunogenicity cohort
28 Were excluded from the
ATP immunogenicity cohort
121 Were included in the ATP
immunogenicity cohort
123 Were included in the ATP
immunogenicity cohort
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tion of M. tuberculosis–infected adults with an ad-
juvanted subunit vaccine containing two M. tuber-
culosis proteins. The finding of efficacy for the 
primary end point was supported by the sensitiv-
ity analysis and by the analysis of the second case 
definition. The analyses of less stringent case defi-
nitions 3 to 5 did not show significant differences 
between the M72/AS01E group and the placebo 
group. The results with respect to the safety and 
reactogenicity profile are consistent with those 
observed previously. Antibody responses were in 
the same range as observed previously in M72/
AS01E-vaccinated adults living in regions in which 
tuberculosis is endemic.9,10
Because the trial included only M. tuberculosis–
infected persons, it is not possible to determine 
the extent to which M. tuberculosis infection influ-
ences vaccine efficacy. In previous tuberculosis 
efficacy trials, the viral-vectored candidate vaccine 
MVA85A showed no additional protection beyond 
that provided by the BCG vaccine in infants not 
infected with M. tuberculosis24; multiple doses of 
inactivated M. vaccae (obuense) that were adminis-
tered to HIV-infected adults reduced the risk of 
definite tuberculosis, which was a secondary end 
point, by 39%, with no effect modification accord-
ing to baseline M. tuberculosis infection status.25 A 
global tuberculosis vaccination strategy would ide-
ally target both M. tuberculosis–infected and unin-
fected adolescents and adults.4 Our findings in 
M. tuberculosis–infected adults complement those 
of a recent trial showing 45% efficacy of BCG 
revaccination for protection of adolescents not 
infected with M. tuberculosis against sustained QFT 
seroconversion.26 Our results suggest further eval-
uation of M72/AS01E as a possible vaccination 
strategy against tuberculosis.
Recent research suggests that progression from 
latent M. tuberculosis infection to active tuberculosis 
is not a single definitive event but rather a tran-
sition through a spectrum of inflammatory and 
infected states that reflect the activity of individ-
ual granulomas.27 Clinically, this spectrum results 
in heterogeneous disease states within and be-
tween persons. In this trial, participants with 
clinical suspicion of tuberculosis underwent diag-
nostic investigation. Approximately one third of 
confirmed cases of pulmonary tuberculosis were 
confirmed by a single test of the six performed 
(either culture or PCR assay). “Single positive” 
cases were evenly distributed between the vaccine 
and placebo groups and became positive by cul-
ture (7 cases) after an unusually long period or by 
PCR assay (3 cases) after an unusually high num-
ber of amplification cycles. We hypothesize that 
active surveillance of trial participants detected 
pulmonary tuberculosis with a low bacterial load, 
which would be consistent with early stages of 
disease or reinfection. Three (of 10) “single posi-
tive” participants (with blinding as to trial-group 
assignment) did not receive tuberculosis treatment 
and remained well, which suggests successful im-
mune control and lack of disease progression.
The sensitivity analysis suggested higher vac-
cine efficacy among participants with at least two 
positive tests, which would be consistent with a 
higher bacterial load. Piecewise and time-to-event 
analyses did not show significant vaccine efficacy 
during year 1. We hypothesize that this may be 
because at least some persons in whom active tu-
berculosis developed during this time already 
had incipient tuberculosis at baseline, against 
which the vaccine would not be expected to have 
Figure 1 (facing page). Screening and Randomization.
Of the 5 participants who were excluded from the to-
tal efficacy cohort, 2 were found to have active tuber-
culosis at trial entry and 3 had a history of active tu-
berculosis; blinding to trial-group assignment remains 
in effect. A total of 285 participants (blinding to trial-
group assignment remains in effect) were excluded 
from the according-to-protocol (ATP) efficacy cohort 
for the following reasons: administration of vaccine 
forbidden in the protocol (19 participants), random-
ization error (2), randomization code broken at the in-
vestigator site (1), trial regimen not administered ac-
cording to the protocol (3), participant did not receive 
two doses of the trial regimen (236), participant did 
not enter the efficacy evaluation period 1 month after 
dose 2 (11), active tuberculosis (any case definition) 
diagnosed up to 1 month after dose 2 (1), administra-
tion of medication forbidden by the protocol (2), non-
adherence to the trial-regimen schedule (3), and par-
ticipant did not meet inclusion criteria or met 
exclusion criteria (7). A total of 56 participants (blind-
ing to trial-group assignment remains in effect) were 
excluded from the ATP immunogenicity cohort for the 
following reasons: administration of vaccine forbidden 
in the protocol (4 participants), sputum positive for 
Mycobacterium tuberculosis at baseline (1), participant 
did not meet inclusion criteria or met exclusion crite-
ria (1), concomitant infection (active tuberculosis) that 
was related to the vaccine and that may influence im-
mune response (1), concomitant infection (participant 
became HIV-infected) that was not related to the vac-
cine and that may influence immune response (7), non-
adherence to the trial-regimen schedule (3), nonadher-
ence to the blood-sampling schedule (9), essential 
serologic data missing (all post-vaccination time points 
at month 2 and month 12 missing) (15), and participant 
did not receive two doses of the trial regimen (15).
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an effect, or that the trial did not have power to 
show a difference in the first year, or that this 
was a chance finding. Although we made efforts 
to exclude participants with active tuberculosis at 
screening (single PCR test on one sputum speci-
men), a limitation of the trial was that we could 
not rule out that early active cases were missed, 
given the frequently low bacillary load and spo-
radic nature of bacillary shedding in early stages 
of tuberculosis disease.28
Unexpectedly, we observed a higher point esti-
mate for vaccine efficacy in men than in women 
(attack rate in the placebo group, 0.6 per 100 per-
son-years for men and women) and in participants 
25 years of age or younger than in those older 
than 25 years of age (attack rate in the placebo 
group, 0.8 and 0.4 per 100 person-years, respec-
tively). A post hoc demographic analysis showed 
an imbalance in sex among participants 25 years 
of age or younger (66% men and 34% women), 
whereas the older age group was well-balanced, 
which suggests that the apparent difference ob-
served according to sex was confounded by the 
effect of age and is probably an artifact. In addi-
tion, in a post hoc interaction test, vaccine efficacy 
did not seem to differ significantly according to 
sex (P = 0.31), whereas efficacy tended to be hetero-
geneous across age groups (P = 0.07 in a hierarchi-
cal model containing both interactions). Interpre-
tation of all post hoc and exploratory subgroup 
analyses should be performed cautiously, because 
the trial was not powered to detect differences 
between subgroups, and multiple comparisons 
were not accounted for.
Age could potentially affect vaccine efficacy 
through a differential vaccine effect according to 
the time since primary M. tuberculosis infection or 
BCG priming.29 We hypothesize that those with 
less-recent primary infection are more likely to 
have the infection under immune-system control, 
with little additional benefit conveyed by vaccina-
tion. Increasing age is associated with increased 
Figure 2. Kaplan–Meier Estimate of Definite Pulmonary Tuberculosis (TB) Disease Not Associated with HIV Infection 
(First Case Definition).
The analysis was conducted in the according-to-protocol efficacy cohort. The time shown is the time from the be-
ginning of follow-up (i.e., 30 days after dose 2). The inset shows the same data on an enlarged y axis. The decreased 
number at risk after 24 months reflects the participants for whom follow-up after this time point had not occurred 
at the date of data lock.
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Covariate  
and Group
No./Total  
No.†
Person-yr of  
Follow-up
Rate per 100 Person-yr  
(90% CI) Vaccine Efficacy
% (90% CI) % (95% CI)
Overall
M72/AS01E 10/1623 3707.03 0.3 (0.2 to 0.5) 54.0 (13.9 to 75.4) 54.0 (2.9 to 78.2)
Placebo 22/1660 3747.43 0.6 (0.4 to 0.8)
Diabetes
No
M72/AS01E 10/1615 3688.14 0.3 (0.2 to 0.5) 53.9 (13.8 to 75.4) 53.9 (2.8 to 78.2)
Placebo 22/1655 3735.22 0.6 (0.4 to 0.8)
Yes
M72/AS01E 0/7 16.29 0 0 0
Placebo 0/5 12.21 0
Sex
Female
M72/AS01E 7/679 1572.39 0.4 (0.2 to 0.8) 27.4 (−63.4 to 67.7) 27.4 (−90.8 to 72.4)
Placebo 10/708 1627.29 0.6 (0.4 to 1.0)
Male
M72/AS01E 3/944 2134.63 0.1 (0.1 to 0.4) 75.2 (28.3 to 91.4) 75.2 (12.2 to 93.0)
Placebo 12/952 2120.13 0.6 (0.4 to 0.9)
Country
Kenya
M72/AS01E 2/242 549.09 0.4 (0.1 to 1.2) −101.6 (−1411.7 to 73.1) −101.6 (−2123.7 to 81.7)
Placebo 1/246 550.84 0.2 (0 to 0.9)
South Africa
M72/AS01E 8/1307 3008.71 0.3 (0.1 to 0.5) 59.3 (19.0 to 79.6) 59.3 (7.6 to 82.1)
Placebo 20/1344 3058.97 0.7 (0.5 to 0.9)
Zambia
M72/AS01E 0/74 — —
Placebo 1/70 — —
Current smoker
No
M72/AS01E 3/791 1812.82 0.2 (0.1 to 0.4) 56.0 (−36.9 to 85.9) 56.0 (−70.1 to 88.6)
Placebo 7/818 1856.06 0.4 (0.2 to 0.7)
Yes
M72/AS01E 7/831 1891.62 0.4 (0.2 to 0.7) 53.3 (0.8 to 78.0) 53.3 (−14.6 to 80.9)
Placebo 15/842 1891.36 0.8 (0.5 to 1.2)
Age
≤25 yr
M72/AS01E 2/705 1599.77 0.1 (0 to 0.4) 84.4 (45.7 to 95.5) 84.4 (31.0 to 96.5)
Placebo 13/724 1616.66 0.8 (0.5 to 1.3)
Table 3. Vaccine Efficacy against Definite Pulmonary TB Disease Not Associated with HIV Infection (Case Definition 1) for Each Covariate 
and Overall.*
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probability of more remote infection, according 
to several studies30-34 and screening data from the 
current trial, in which 55.1 to 66.6% of the screened 
persons were already infected with M. tuberculo-
sis.31 Alternatively, the circumstances that lead to 
reactivation may be less amenable to immuno-
logic control by booster vaccination further from 
primary BCG vaccination or initial M. tuberculosis 
infection, and therefore the benefits of vaccina-
tion may be more limited. Given the age of the 
trial population, immune senescence is unlikely 
to have affected vaccine efficacy.
In our trial, PCR assay had sensitivity of 80% 
as compared with culture (Table S8 in the Sup-
plementary Appendix), a finding consistent with 
more events meeting the first case definition than 
the second. Future trials of vaccine efficacy should 
therefore use automated liquid culture in addition 
to PCR assay to maximize case detection. Tuber-
culosis treatment of adult drug-sensitive pulmo-
nary tuberculosis leads to negative sputum culture 
and PCR assay at 8 weeks in some participants35; 
therefore, case definitions 3 and 4 probably un-
derestimate the incidence of tuberculosis.
Strengths of the trial were the inclusion of a 
large, well-defined cohort, exclusion of active tu-
berculosis disease at baseline, statistical power to 
address the primary end point, and the use of 
alternative case definitions for the efficacy end 
point that reflect applicability in the real world. 
Finally, 99% of the participants consented to bio-
banking of blood samples obtained before and 
after administration of the trial regimen. These 
samples offer the opportunity to discover poten-
tial immune correlates of vaccine-mediated pro-
tection against tuberculosis, which, if confirmed, 
will be useful to reduce the size of future efficacy 
trials (ClinicalTrials.gov number, NCT02097095). 
(Fig. S3 in the Supplementary Appendix elaborates 
on the clinical relevance of the proof-of-concept 
trial in a form that could be shared with patients 
by health care professionals.)
In conclusion, we found that the incidence of 
pulmonary tuberculosis was significantly lower 
with M72/AS01E than with placebo among healthy 
M. tuberculosis–infected, largely BCG-vaccinated, 
HIV-negative adults. These promising results pro-
vide an opportunity to better understand the 
Covariate  
and Group
No./Total  
No.†
Person-yr of  
Follow-up
Rate per 100 Person-yr  
(90% CI) Vaccine Efficacy
% (90% CI) % (95% CI)
>25 yr
M72/AS01E 8/918 2107.25 0.4 (0.2 to 0.7) 10.2 (−99.6 to 59.6) 10.2 (−132.7 to 65.4)
Placebo 9/936 2130.77 0.4 (0.2 to 0.7)
BCG vaccination‡
No
M72/AS01E X/136§ — —
Placebo X/149§ — —
Yes
M72/AS01E 8/1243 2823.92 0.3 (0.2 to 0.5) 55.8 (11.0 to 78.0) 55.8 (−1.8 to 80.8)
Placebo 18/1247 2808.34 0.6 (0.4 to 0.9)
Unknown
M72/AS01E 1/243 555.68 0.2 (0 to 0.9) 73.1 (−69.1 to 95.7) 73.1 (−140.5 to 97.0)
Placebo 4/264 591.74 0.7 (0.3 to 1.5)
*  The analysis was conducted with an unadjusted Cox regression model in the according-to-protocol efficacy cohort.
†  Shown is the number of participants meeting the first case definition and the total number of participants.
‡  BCG (bacille Calmette–Guérin) vaccination indicates documentation of previous BCG vaccination or the presence of a BCG scar.
§  A total of 136 participants in the M72/AS01E group and 149 in the placebo group had no previous BCG vaccination and no BCG scar.  
Of these 285 participants, 1 met the first case definition, and blinding to trial-group assignment remains in effect.
Table 3. (Continued.)
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mechanisms by which this vaccine may confer 
protection against tuberculosis and support its 
further evaluation.
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Variable
M72/AS01E 
(N = 1786)
Placebo 
(N = 1787)
Relative Risk  
(95% CI)
No. of 
Participants % (95% CI)
No. of 
Participants % (95% CI)
30 Days after vaccination
≥1 Unsolicited symptom 1203 67.4 (65.1–69.5) 812 45.4 (43.1–47.8) 1.48 (1.35–1.62)
≥1 Causally related unsolicited symptom 992 55.5 (53.2–57.9) 371 20.8 (18.9–22.7) 2.68 (2.37–3.02)
≥1 Grade 3 symptom 234 13.1 (11.6–14.8) 124 6.9 (5.8–8.2) 1.89 (1.51–2.37)
≥1 Causally related grade 3 symptom 177 9.9 (8.6–11.4) 27 1.5 (1.0–2.2) 6.56 (4.36–10.23)
≥1 Serious adverse event† 10 0.6 (0.3–1.0) 17 1.0 (0.6–1.5)
≥1 Causally related serious adverse event‡ 1 0.1 (0–0.3) 1 0.1 (0–0.3)
Within 6 mo after vaccination
≥1 Serious adverse event§ 29 1.6 (1.1–2.3) 33 1.8 (1.3–2.6)
≥1 Causally related serious adverse event‡ 1 0.1 (0–0.3) 1 0.1 (0–0.3)
Potential immune-mediated disease¶ 2 0.1 (0–0.4) 5 0.3 (0.1–0.7)
Entire trial period
Death‖ 7 0.4 (0.2–0.8) 17 1.0 (0.6–1.5)
Death by injury** 6 — 8 —
*  The causal relationship between the trial regimen and the symptom or serious adverse event was determined by the site investigators.
†  Serious adverse events included hypochromic anemia, cardiac disorder, ventricular tachycardia, gastric ulcer, pyrexia, acute HIV infection, 
cellulitis, lymph-node tuberculosis, malaria, pelvic inflammatory disease, pneumonia, tuberculosis, gunshot wound, head injury, limb injury, 
traumatic pneumothorax, soft-tissue injury, traumatic hemothorax, wound hematoma, hypertensive encephalopathy, seizure, depression, 
schizophrenia, acute kidney injury, uterine polyp, and hypertension. Blinding to trial-group assignment remains in effect.
‡  Causally related serious adverse events included pyrexia and hypertensive encephalopathy, with blinding to trial-group assignment still in 
effect.
§  For details on serious adverse events, see Table S7 in the Supplementary Appendix.
¶  Cases of potential immune-mediated disease included two cases of optic neuritis and one case each of immune thrombocytopenic purpura, 
Basedow (Graves’) disease, gout, erythema multiforme, and morbilliform rash. Blinding to trial-group assignment remains in effect.
‖  In addition to the 14 deaths for which a coding of death from injury was applied, there were 3 cases of death from unknown cause or sud-
den death and 1 death each from cardiac disorder, hepatic cirrhosis and hepatic encephalopathy, acute HIV infection, pneumonia and 
suspicion of gastrointestinal tuberculosis, stroke, completed suicide, and dyspnea (drug overdose). For these 10 deaths, blinding to trial-
group assignment remains in effect.
**  Types of injury included gunshot, stab wound, road traffic accident, and burn.
Table 4. Summary of Vaccine Safety (Total Vaccinated Cohort).*
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